<DOC>
	<DOCNO>NCT01950273</DOCNO>
	<brief_summary>The primary objective study assess pharmacokinetic ( PK ) similarity Boehringer Ingelheim ( BI ) 695500 vs. rituximab ( MabThera® ) previously untreated patient low tumor burden follicular lymphoma ( LTBFL ) . The secondary objective study evaluate pharmacodynamics ( PD ) , safety , anti-tumor activity BI 695500 vs. rituximab ( MabThera® ) , well presence anti-drug antibody ( ADAs ) .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics BI 695500 vs. Rituximab First Line-treatment Patients With Low Tumor Burden Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Inclusion criterion : Must give write informed consent willing follow CTP . Male female patient , least 18 year age Screening . Histologicallyconfirmed , stage II IV NHL ( CD20+ FL Grades 1 , 2 , 3a ) . Low tumor burden accord GELF criterion nodal extranodal involvement 7 cm , 3 nodal site diameter &gt; 3 cm , B symptom ( i.e. , fever &gt; 38°C , weight loss unexplained loss &gt; 10 % body weight past 6 month , sweat presence drench night sweat ) , significant splenomegaly , significant serious effusion , complication organ compression , less 5x10^9/L circulate tumor cell . Availability archive tumor sample prior screen . Patients previously treat FL . ECOG performance status 0 1 . Have least 1 measurable lesion per International Working Group ( IWG ) criterion 2007 Screening ( lesion clearly measurable least 2 perpendicular dimension ; see Appendix 10.1 detail ) . Adequate hematological function ( unless abnormality relate lymphoma infiltration bone marrow ) within 28 day prior randomization , include : hemoglobin =9.0 g/dL ( =5.6 mmol/L ) . absolute neutrophil count =1.5 × 10^9/L . platelet count =100 × 10^9/L . Adequate renal liver function : serum creatinine &lt; 2.0 mg/dL ( &lt; 176.8 mcmol/L ) . total bilirubin &lt; 2.0 mg/dL ( &lt; 34 mcmol/L ) except patient Gilbert 's Syndrome Hemolysis . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 3 x upper limit normal ( ULN ) ( &lt; 5 x ULN acceptable abnormality think relate hepatic infiltration FL ) . For participant reproductive potential ( male female ) , use medically acceptable method contraception trial , i.e. , combination 2 form effective contraception ( defined hormonal contraception , intrauterine device , condom spermicide , etc. ) . Females childbearing potential ( include tubal ligation ) males female partner childbearing potential must also agree use acceptable method contraception ( see ) 12 month follow completion discontinuation trial medication . Exclusion criterion : Transformation highgrade lymphoma ( secondary lowgrade lymphoma ) . Presence history central nervous system lymphoma . Patients receive current treatment corticosteroid must receive dose exceed 20 mg/day prednisone equivalent . Patients prior concomitant malignancy within 5 year prior screen except nonmelanoma skin cancer , adequately treat carcinoma situ cervix , adequately treat breast cancer situ , localized prostate cancer stage T1c provide patient underwent curative treatment , remain relapse free . Major surgery ( exclude lymph node biopsy ) within 28 day prior randomization . Active , chronic persistent infection might worsen immunosuppressive treatment ( e.g. , Human Immunodeficiency Virus [ HIV ] , Hepatitis C Virus [ HCV ] , Herpes Zoster ) ; positive HIV tuberculosis Screening . Patients serological evidence HBV infection . Patients seropositive HBV vaccine eligible . HBV positive patient may participate follow consultation hepatitis expert regard monitoring use HBV antiviral therapy , provide agree receive treatment indicate . Serious underlie medical condition , , per investigator 's discretion , could impair ability patient participate trial ( include limit ongoing active infection , severe immunosuppression , uncontrolled diabetes mellitus , gastric ulcer , active autoimmune disease ) ; patient significant cardiac disease , include limited congestive heart failure Class III IV NYHA classification ; uncontrolled angina arrhythmia ; uncontrolled severe cardiovascular cerebrovascular disease . Known hypersensitivity allergy murine product . History severe allergic reaction anaphylactic reaction biological agent history hypersensitivity component trial drug . Receipt live/attenuated vaccine within 12 week prior Screening Visit . Prior treatment BI 695500 and/or rituximab . Patients receive prior therapy use monoclonal antibody exclude ; apply biological drug growth factor anticoagulant . Treatment within clinical trial within 4 week prior initiation trial treatment . Patients receive treatment drug receive regulatory approval indication within 4 week minimum 5 halflives , whichever longer , initial dose trial medication . Any coexist medical psychological condition ( ) preclude participation trial compromise ability give inform consent and/or comply study procedure . Pregnancy breast feeding . For woman childbearing potential , positive serum pregnancy test Screening Visit . Patients significant cardiac disease , include limited congestive heart failure Class III IV New York Heart Association ( NYHA ) classification ; uncontrolled angina arrhythmia ; uncontrolled severe cardiovascular cerebrovascular disease ; uncontrolled hypertension .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>